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Abstract
To detect genes with CpG sites that display methylation patterns that are characteristic of acute lymphoblastic leukemia
(ALL) cells, we compared the methylation patterns of cells taken at diagnosis from 20 patients with pediatric ALL to the
methylation patterns in mononuclear cells from bone marrow of the same patients during remission and in non-leukemic
control cells from bone marrow or blood. Using a custom-designed assay, we measured the methylation levels of 1,320 CpG
sites in regulatory regions of 413 genes that were analyzed because they display allele-specific gene expression (ASE) in ALL
cells. The rationale for our selection of CpG sites was that ASE could be the result of allele-specific methylation in the
promoter regions of the genes. We found that the ALL cells had methylation profiles that allowed distinction between ALL
cells and control cells. Using stringent criteria for calling differential methylation, we identified 28 CpG sites in 24 genes with
recurrent differences in their methylation levels between ALL cells and control cells. Twenty of the differentially methylated
genes were hypermethylated in the ALL cells, and as many as nine of them (AMICA1, CPNE7, CR1, DBC1, EYA4, LGALS8, RYR3,
UQCRFS1, WDR35) have functions in cell signaling and/or apoptosis. The methylation levels of a subset of the genes were
consistent with an inverse relationship with the mRNA expression levels in a large number of ALL cells from published data
sets, supporting a potential biological effect of the methylation signatures and their application for diagnostic purposes.
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Introduction
Acute lymphoblastic leukemia (ALL) is the most common
childhood malignancy accounting for 25% of all childhood
cancers in developed countries. ALL originates from the malignant
transformation of lymphocyte progenitor cells into leukemic cells
in the B-cell and T-cell lineages [1]. However, most of the known
large scale genetic aberrations in ALL are not alone sufficient to
induce the disease [2], suggesting that there are other genetic or
epigenetic alterations that act in leukemic transformation.
In mammalian genomes, methylation of the C-residue in CpG
dinucleotides plays an important role in regulating gene expression
[3,4]. DNA methylation is maintained by DNA methyltransferases
(DNMTs). Alterations in the expression of DNMTs in blood
progenitor cells results in extensive changes in methylation
patterns, which may lead to leukemogenesis [5]. Treatment with
inhibitors of DNA methylation, such as 59-azacytidine have
therapeutic benefits in leukemia [6], indicating that the methyl-
ation changes are functionally important. In cancer, the regions
near transcription start sites often show increased methylation
levels, as opposed to an overall decrease in DNA methylation on
the genome-wide level [7,8,9]. DNA hypermethylation in the
promoters of putative tumor suppressor genes has been found to
correlate with resistance against chemotherapy in ALL [10]. We
and others have shown that the methylation levels of sets of genes
have potential as prognostic markers for risk of relapse in pediatric
ALL [11,12]. Moreover, two studies have suggested that minimal
residual disease in leukemia patients can be detected by the
methylation status of only a few genes [13,14]. Thus, epigenetic
perturbation of DNA methylation can be a valuable source of
information for understanding the biology of gene regulation,
phenotypic diversity, and treatment outcome in pediatric ALL.
In a previous genome-wide survey of 8,000 genes in 197 bone
marrow or blood samples from patients with pediatric ALL, we
identified .400 genes that displayed allele-specific gene expression
(ASE) [4]. The observed ASE indicates that the expression of these
genes could be regulated by DNA methylation that silences or
activates gene expression in an allele-specific manner. The
methylation pattern of the genes with ASE allowed classification of
ALL subtypesand stratification of patientsintoprognosticsubgroups
[11].Inthecurrentstudy,wehypothesizedthattheselectionofgenes
based on genome-wide ASE analysis would enrich for genes with
functional CpG site methylation that could be involved in the
pathogenesis of ALL. Our aim was to identify genes that display
aberrant DNA methylation independently of cytogenetic ALL
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34513subtype for further mechanistic studies of ALL. We investigated how
the methylation status of the 1,320 CpG sites in genes with ASE
differs between ALL samples taken at diagnosis and matched bone
marrow samples from the same patients during and after induction
therapy, when the patients were in remission, and in control cells
from bone marrow or blood of non-leukemic individuals.
Materials and Methods
Samples from patients and controls
Mononuclear cells were isolated from bone marrow aspirates or
peripheral blood cells by 1.077 g/mL Ficoll-Isopaque (Pharmacia)
density-gradient centrifugation from 63 samples. The samples
consisted of 20 bone marrow samples taken at diagnosis of ALL,
30 follow-up samples from bone marrow samples taken from the
same patients during therapy, and 13 non-leukemic control samples,
of which 11 were from bone marrow and two were from peripheral
blood of children the same age as the patients. The clinical and
cytogenetic information for the patients is provided in Table 1.T h e
patients were treated according to the ALL 2000 protocol of the
Nordic Society of Pediatric Oncology (NOPHO) [15], in which no
DNA-demethylating drugs are used. The proportion of leukemic
cells was estimated in each sample by light microscopy in May-
Gru ¨nwald-Giemsa–stained cytocentrifugate preparations. The pro-
Table 1. Clinical information for the 20 patients with acute lymphoblastic leukemia and 13 controls included in the study.
Patient ID
Immuno-
phenotype Genetic subtype
Age at diagnosis,
years sex WBC count
a
NOPHO treatment
protocol
b
Remission
samples
c
Patient_1 BCP t(4;11)(q21;q23) 0.8 female 99.7 infant 50
Patient_2 BCP amp(21) 4.3 male 11.6 IR 106
Patient_3 BCP amp(21) 5.9 female 4.3 SR 106
Patient_4 BCP HeH 3.3 male 95.0 HR 106
Patient_5 BCP HeH 6 male 11.2 IR 29, 50,106
Patient_6 BCP HeH 2.6 male 7.2 SR 29, 50,106
Patient_7 BCP HeH 3.5 male 5.0 HR 106
Patient_8 BCP HeH 3.8 male 3.0 SR 29, 50,106
Patient_9 BCP HeH 14.1 female 24.5 IR 29, 50,106
Patient_10 BCP HeH 1.9 male 39.6 HR 29, 50,106
Patient_11 BCP unknown 5.5 female 15.2 HR 106
Patient_12 BCP unknown 12 male 43.9 HR 106
Patient_13 BCP normal 13.2 male 24.0 IR 106
Patient_14 BCP t(12;21) (p13;q22) 6.2 female 4.2 SR 106
Patient_15 BCP t(12;21) (p13;q22) 3.7 male 12.3 IR 50
Patient_16 BCP t(9;22) (q34;q11) 11.2 male 64.4 HR 106
Patient_17 T-ALL T-ALL 13.9 female 139.0 HR 106
Patient_18 T-ALL T-ALL 10.3 male 244.0 HR 106
Patient_19 T-ALL T-ALL 4.3 male 107.0 HR 50
Patient_20 T-ALL T-ALL 7.7 male 44.4 HR 50
Non-Leukemic 1 NA NA 4.1 female NA NA NA
Non-Leukemic 2 NA NA 0.2 male NA NA NA
Non-Leukemic 3 NA NA 0.6 female NA NA NA
Non-Leukemic 4 NA NA 8.3 female NA NA NA
Non-Leukemic 5 NA NA 6.9 female NA NA NA
Non-Leukemic 6 NA NA 14.7 male NA NA NA
Non-Leukemic 7 NA NA 0.9 male NA NA NA
Non-Leukemic 8 NA NA 15.3 male NA NA NA
Non-Leukemic 9 NA NA 14.4 male NA NA NA
Non-Leukemic 10 NA NA 5.1 male NA NA NA
Non-Leukemic 11 NA NA 4.0 female NA NA NA
Non-Leukemic 12 NA NA 14.3 female NA NA NA
Non-Leukemic 13 NA NA 1.1 female NA NA NA
BCP indicates B-cell precursor ALL; T-ALL, T-cell ALL; HeH, high hyperdiploidy; amp(21), amplification of chr 21; HR, high risk; SR, standard risk; IR, intermediate risk; NA,
not available.
aWhite blood cell count at diagnosis (10
9/L).
bThe NOPHO ALL 2000 protocol was used.
cDNA from was available from bone marrow taken from the patients on day 29,50, and/or 106 after the initiation of therapy, all patients were in morphological
remission with less than 5% leukemic blasts.
doi:10.1371/journal.pone.0034513.t001
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included in this study. The matched patient samples taken during
therapy at days 29, 50 and 106 contained less than 5% leukemic
blasts, indicating that the patients were in morphological remission.
The non-leukemic control cells were obtained from sex- and age-
matchedpediatricpatientswith aninitialsuspicionofleukemia,from
which an initial ALL diagnosis was excluded by negative diagnostic
tests and clinical follow-up (Table 1). DNA was extracted from cell
pelletsbytheAllPrepDNA/RNAMiniKit(Qiagen)ortheQIAamp
DNA Blood Mini Kit (Qiagen). The Regional Ethics Committee in
Uppsala, Sweden approved the study, and the patients and/or their
guardians provided written informed consent. The study was
conducted in accordance with the Declaration of Helsinki.
DNA methylation analysis
A custom-designed panel of CpG sites was analyzed to
determine the methylation levels of 1,536 CpG sites located 2 kb
upstream to 1 kb downstream of the transcription start site of 416
genes [4]. Six hundred ng of genomic DNA was treated with
sodium bisulfite (EZ-96 DNA Methylation Kit, Zymo Research)
for subsequent genotyping by the Golden Gate Assay (Illumina
Inc.). The methylation level of each CpG site is obtained from the
genotyping assay as a b-value ranging from 0.0–1.0, which
corresponds to no methylation of either allele to complete
methylation of both alleles of the analyzed genes. Genotyping
and quality control were performed as previously described [11].
After quality filtering, there were 1,320 CpG sites distributed over
413 gene regions, with 1–10 CpG sites per gene, remaining for
analysis (Table S1). We previously reported that the concordance
between the methylation levels determined by the Golden Gate
assay and by Sanger sequencing of bisulfite-converted DNA for
five randomly selected CpG sites was 87% [11] (Figure S1).
Moreover, the concordance between the methylation levels of 21
ALL samples run in replicate using the GoldenGate Assay was
high, with a median site-wise Pearson correlation coefficient
R=0.88 for the 28 CpG sites highlighted in the present study
(Table S2).
Gene expression data
Genome-wide gene expression data was retrieved from two
ALL datasets via the Oncomine tool (Compendia Bioscience). The
first dataset contained expression data for 98 ALL patients and
bone marrow cells from six healthy controls [16]. The second
dataset contained expression data for 533 ALL patients and
PBMCs from 74 healthy controls [17].
Statistical analyses
The similarity of individual methylation profiles was assessed
using the Pearson correlation coefficient (R). Hierarchical
clustering was performed by ‘‘hclust’’ with one minus the
correlation coefficient as the similarity measure for individual
samples and between individual CpG sites. The Wilcoxon Signed-
Rank test was used to identify CpG sites with differences in
methylation between the paired diagnostic and remission samples.
The Wilcoxon Rank-Sum test was used to test for differentially
methylated CpG sites between diagnostic BCP and T-ALL
samples. Where indicated, P-values were adjusted for multiple
testing with the Benjamini-Hochberg method. The Friedman’s test
was used to identify CpG sites with differential methylation in
serial bone marrow samples taken from the same individuals. All
statistical analyses were performed in R. Gene lists were analyzed
by Ingenuity Pathway Analysis (IPA) (IngenuityH Systems).
Pathway-associated P-values were calculated with a Fisher’s exact
test. The P-value is based on the enrichment of differentially
methylated genes compared to the 413 genes with ASE that were
analyzed.
Figure 1. Correlation matrix and variability of the methylation levels measured at 1,320 CpG sites across the 63 samples included in
the study. (A) Each individual sample is indicated by a black line on the axes. The methylation levels in the samples taken at remission during
induction therapy at day 29 and during consolidation therapy at days 50 and 106 are highly correlated with the methylation levels in the non-
leukemic samples (median Pearson’s correlation coefficient (R)=0.96), while the diagnostic ALL samples are less similar both to each other and to the
samples taken after treatment, and to the non-leukemic samples (median R=0.83). The scale for the correlation coefficients is shown to the right of
the matrix. The red color indicates higher correlation (greater similarity), while the light yellow indicates less correlation (less similarity). (B) Histograms
of the standard deviations (SD) for the methylation levels measured for 1,320 CpG sites across 20 ALL samples (blue) and across the combined 33
remission samples and 13 non-leukemic controls (red). SD bins are shown on the horizontal axis. The vertical bars show the proportion of
observations in each SD bin. The CpG sites show greater variability in the ALL samples than in the remission samples and non-leukemic controls
(Wilcoxon Rank-Sum P,0.001).
doi:10.1371/journal.pone.0034513.g001
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Analysis of differential DNA methylation between
diagnostic ALL samples, remission samples, and controls
To identify genes with differential DNA methylation, we
compared the methylation levels of 1,320 CpG sites in
mononuclear cells from bone marrow taken at the time of ALL
diagnosis to bone marrow mononuclear cells from the same
patients at day 29, 50 or 106 of therapy, when the patients were in
remission, and to bone marrow and peripheral blood mononuclear
cells from non-leukemic controls. The data for the 1,320 CpG sites
from all samples is available in the Supporting Information (Table
S1). We found that the methylation pattern across the 1,320 CpG
sites in each of the bone marrow samples of ALL patients were
distinct from the samples taken at remission and from the non-
leukemic controls (Figure 1A). The methylation levels of each
individual CpG site displayed low variability between samples with
a mean standard deviation (SD) of 0.045 across all the 1,320 CpG
sites in the DNA samples taken at remission and in the DNA
samples from the non-leukemic controls. In contrast, the
methylation levels of the CpG site displayed higher variability
between samples across the 1,320 CpG sites (mean SD=0.12) in
the ALL cells taken at diagnosis (Figure 1B). We did not detect
any statistically significant differences (Permuted Friedman’s
P,0.01 and Db.0.10) when the methylation levels of the DNA
samples from five ALL patients collected at different time points
during remission were compared group-wise (day 29, 50, 106).
The small sample size in this analysis precludes detection of
statistically significant differences, but we cannot exclude the
possibility that there might be differences in CpG site methylation
Table 2. CpG sites with differential methylation between acute lymphoblastic leukemia cells and remission cells.
Median b-value (range)
Gene
symbol
a CpG site location
b
Distance from
TSS
c ALL diagnosis Remission
Median Db-
value
d
N Db-
value.0.3
e
Adjusted P-
value
f
mRNA
expression
g
ACCS 11p11 44,044,910 477 0.58 (0.03–0.92) 0.18 (0.09–0.49) 0.41 12 4.30E-04 nc
ACY3 11q13 67,174,534 172 0.04 (0.02–0.69) 0.41 (0.18–0.67) 20.37 12 1.94E-04 +[16]
AMICA1 11q23.3 117,602,131 1,204 0.80 (0.03–0.94) 0.35 (0.07–0.57) 0.45 15 6.53E-04 2[16][17]
CD300LF 17q25.2 70,220,061 642 0.67 (0.35–0.85) 0.18 (0.04–0.44) 0.49 15 1.48E-04 2[16][17]
COL6A2 21q22.3 46,343,270 800 0.44 (0.07–0.94) 0.03 (0.02–0.18) 0.41 14 1.48E-04 nc
COL6A2 21q22.3 46,342,715 245 0.34 (0.02–0.92) 0.03 (0.02–0.05) 0.32 10 1.94E-04 nc
CPNE7 16q24.3 88,170,539 862 0.86 (0.28–0.95) 0.25 (0.12–0.67) 0.61 15 1.94E-04 nc
CR1 1q32 205,736,601 476 0.46 (0.19–0.75) 0.04 (0.02–0.24) 0.41 13 1.48E-04 2[17]
DBC1* 9q32-q33 121,170,638 884 0.61 (0.06–0.93) 0.05 (0.03–0.13) 0.56 15 1.48E-04 2[16]
EYA4 6q23 133,605,061 855 0.70 (0.32–0.84) 0.10 (0.04–0.20) 0.60 19 1.48E-04 nc
EYA4 6q23 133,603,412 2794 0.42 (0.03–0.87) 0.04 (0.04–0.09) 0.37 12 6.53E-04 nc
FAM83A 8q24.13 124,263,705 2228 0.66 (0.25–0.82) 0.36 (0.17–0.57) 0.31 11 5.36E-04 nc
FXYD2 11q23 117,203,859 158 0.22 (0.03–0.51) 0.67 (0.56–0.76) 20.45 14 1.48E-04 +[16][17]
FXYD2 11q23 117,203,745 272 0.20 (0.02–0.81) 0.75 (0.59–0.86) 20.55 16 3.93E-04 +[16][17]
LGALS8 1q43 234,751,397 21,963 0.89 (0.35–0.94) 0.49 (0.19–0.85) 0.39 10 5.36E-04 nc
MYBPC2 19q13.33 55,628,143 139 0.06 (0.02–0.88) 0.67 (0.57–0.78) 20.61 15 6.53E-04 +[16]
MYO3A 10p11.1 26,263,054 148 0.57 (0.05–0.90) 0.07 (0.03–0.22) 0.51 14 1.48E-04 nc
MYO3A 10p11.1 26,262,977 2225 0.38 (0.02–0.83) 0.04 (0.03–0.09) 0.34 12 2.70E-04 nc
PI16 6p21.31 37,029,477 2710 0.14 (0.03–0.64) 0.44 (0.29–0.59) 20.31 9 4.30E-04 nc
RUNDC3B* 7q21.12 87,096,478 813 0.45 (0.04–0.80) 0.07 (0.03–0.15) 0.38 13 4.30E-04 nc
RYR3 15q14-q15 31,390,843 374 0.39 (0.06–0.89) 0.07 (0.03–0.18) 0.33 10 1.48E-04 nc
SEC14L4 22q12.1 29,231,446 236 0.44 (0.02–0.72) 0.05 (0.02–0.23) 0.40 12 8.11E-04 2[17]
THSD7A 7p21.3 11,840,245 21,902 0.83 (0.42–0.93) 0.45 (0.19–0.69) 0.39 12 1.48E-04 nc
TMEM2 9q13-q21 73,572,286 942 0.77 (0.04–0.89) 0.22 (0.06–0.49) 0.54 13 4.30E-04 2[16]
UQCRFS1 19q12 34,395,007 2947 0.66 (0.02–0.95) 0.14 (0.02–0.35) 0.51 15 4.30E-04 nc
WDR35 2p24.3 20,052,748 2617 0.76 (0.27–0.91) 0.10 (0.03–0.24) 0.66 17 1.48E-04 nc
ZNF462 9q31.3 108,663,645 21,554 0.66 (0.05–0.90) 0.06 (0.05–0.26) 0.60 16 4.30E-04 nc
ZNF502 3p21.32 44,729,363 221 0.62 (0.11–0.93) 0.03 (0.02–0.22) 0.59 15 1.48E-04 nc
aGene symbol according to the HUGO Gene Nomenclature Committee (http://www.genenames.org/);
*indicates genes selected from the literature;DBC1 [24]; RUNDC3B [25].
bChromosome number and coordinate of the CpG site (Human genome build 36).
cDistance from the transcription start site (TSS); 2, upstream from the TSS; +, downstream from the TSS.
dMedian difference in beta-value between ALL patients at diagnosis and remission for paired samples (ALL-remission).
eNumber of ALL-remission pairs with Db-values larger than 0.30.
fAdjusted Wilcoxon Signed-Rank P-values corrected for multiple testing with the Benjamini Hochberg approach.
gGenes up (+) or down (2) regulated in ALL cells compared to controls according to published datasets [16,17], n.c.=no change.
doi:10.1371/journal.pone.0034513.t002
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treatment.
We applied stringent criteria for detecting CpG sites with
differential methylation between the cells at ALL diagnosis and
bone marrow cells at remission, by requiring a adjusted P-
value,0.001 for the median difference in Db-values between the
two groups and a threshold of 0.30 for calling a CpG site as
differentially methylated. This analysis identified 28 CpG sites in
24 genes with differential methylation between the cells taken at
ALL diagnosis and bone marrow mononuclear cells at remission
(Table 2). A large proportion (45–95%) of the individual sample
pairs fulfilled the criterion of a Db-value.0.3 for the 28 CpG sites.
Hierarchical clustering of the samples at diagnosis (n=20), at
remission (n=30) and the non-leukemic control cells (n=13)
according to the methylation levels of the 28 differentially
methylated CpG sites resulted in unequivocal separation between
the ALL samples and the bone marrow samples at remission
(Figure 2A), with the non-leukemic control samples clustering
together with the samples taken at remission. The CpG sites
displayed two distinct patterns of differential methylation. For 23
Figure 2. Differential methylation in ALL cells. (A) Heatmap of the methylation profiles of the 28 CpG sites that are differentially methylated
between the diagnostic ALL samples, bone marrow cells at remission and non-leukemic bone marrow cells. The ALL samples (orange) and bone
marrow cells during remission (blue) form two distinct groups. Thirteen bone marrow cell samples from non-leukemic controls (purple) cluster
among the samples collected during remission. The scale for the methylation b-values is shown below the heatmap. The elongated heights of the
dendrogram branches between the ALL samples compared to the normal samples illustrate the increased variability in the ALL samples for the 28
CpG sites. Graphs showing the differences in methylation level between CpG sites in the (B) WDR35 and (C) FXYD2 genes at the time of diagnosis (left
vertical axis) and during remission (right vertical axis). The data points for each paired sample are connected with a red line for B-cell precursor (BCP)
samples and with a blue line for T-ALL samples. The corresponding CpG methylation levels in 13 non-leukemic control samples are shown as black
horizontal lines to the right of the graphs. The CpG site at chr2:20,052,748 in the WDR35 gene (B) was hypermethylated in diagnostic ALL samples and
hypomethylated at remission and in non-leukemic controls, while the CpG site at chr11:7,203,745 in the FXYD2 gene (C) displayed the opposite
pattern. The BCP and T-ALL samples display the same pattern of methylation difference in these two genes.
doi:10.1371/journal.pone.0034513.g002
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(Figure 2B), the methylation levels were higher in the ALL cells at
diagnosis than in the bone marrow cells during remission (median
Db=0.66). We also identified five CpG sites with the opposite
pattern, like FXYD2 (Figure 2C), with higher median methylation
levels in the cells at remission (median Db=0.55). Four of the
genes with differential methylation according to the stringent
criteria applied (COL6A2, EYA4, FXYD2, MYO3A) contained two
differentially methylated CpG sites. The methylation levels (b-
values) of the CpG sites in these genes were correlated (R.0.70)
(Figure 3). At less stringent criteria for calling differential
methylation (P,0.05 and Db.0.2) the methylation status of 1–2
additional CpG sites in nine of the genes supported the
corresponding hyper- or hypomethyation (Table S1).
The CpG site in the MYBPC2 gene was differentially methylated
(Wilcoxon Rank-Sum test, P-value,0.001) between ALL cells of
B-cell origin (BCP ALL, n=16) and T-cell origin (T-ALL, n=4),
with hypomethylation in BCP ALL (median b-value=0.04) and
hypermethylation in T-ALL (median b-value=0.75). The other
27 CpG sites did not display differential methylation between BCP
and T-ALL samples (Table S2), indicating that the majority of the
genes identified here based on their methylation profiles are
characteristic for ALL cells, independently of immuno-phenotype.
Regulation of gene expression by DNA methylation
On a genome-wide scale there is an inverse relationship
between DNA methylation in the vicinity of the TSS and mRNA
expression [18]. To examine whether the differentially methylated
CpG sites identified here had potential regulatory functions, we
queried two published sets of mRNA expression data from ALL
cells with data for 98 and 533 ALL samples, respectively [16,17],
for up- or down-regulation of the differentially methylated genes.
In these datasets, the AMICA1, DBC1, CD300LF, CR1, SEC14L4
and TMEM2 genes identified in our study as hypermethylated
were down-regulated and the hypomethylated genes ACY3,
FXYD2, and MYBPC2 were up-regulated with 2-fold differences
in expression levels between ALL cells and control bone marrow
cells [16] or peripheral blood mononuclear cells from healthy
individuals [17] (Table 2) in at least one dataset. The other genes
identified in our differential methylation analysis did not meet the
minimum criteria of 2-fold differential expression.
Biological roles for the genes with differential
methylation
The 24 differentially methylated genes highlighted in our study
(Table 2) were enriched (P,0.05) for functions such as cell-to-cell
Figure 3. Correlation between the methylation levels (b-values) of two CpG sites located in the COL6A2, EYA4, FXYD2 and MYO3A
genes. The Pearson’s correlation coefficients (R) across the 20 acute lymphoblastic leukemia (ALL) samples taken at ALL diagnosis (green) and the 20
matched bone marrow samples taken at remission (blue) for the four genes are shown in panels A–D. The positions of the CpG sites for which the b-
values are plotted are indicated on the axes in each panel (Human Genome Build 36). The inter-individual variation between the pairs of CpG sites in
the remission cells is consistently lower than between the ALL cells, which speaks against the variation in ALL cells arising because of methodological
factors.
doi:10.1371/journal.pone.0034513.g003
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death/apoptosis (CR1, DBC1, EYA4, LGALS8, UQCRFS1)
(Table 3). Among the differentially methylated genes, several
have been previously identified as differentially methylated in
cancer and are known to be involved in ALL. EYA4 is frequently
hypermethylated and down-regulated in colon and esophageal
cancers [19,20]. Expression of LGALS8 and UQCRFS1 are
associated with relapse in T-ALL [21,22] and the COL6A2,
DBC1 and RUNDC3B genes have been found to be hypermethy-
lated and down-regulated in pediatric ALL samples [23,24,25].
The AMICA1 and FXYD2 genes are located near the breakpoint
region of the MLL fusion gene on chromosome 11q23 and are
potential fusion partners with the MLL gene in ALL cells [26,27].
In a recent study, the MY03A and DBC1 genes were included as
methylated markers a panel of 10-genes for detection of bladder
cancer in urine samples [28], which is interesting in light of
mounting evidence for generalized differentially methylated
regions across different cancer types [29]. Besides DBC1, which
is a suspected tumor suppressor gene [30], the precise functions on
the molecular level of the other genes highlighted in our study
have not yet been defined in ALL.
Discussion
In our study of DNA methylation patterns in regulatory
regions of 413 genes known to display ASE in ALL cells [4], we
identified 24 genes with recurrent differential CpG site
methylation that distinguished unequivocally between bone
marrow cells from ALL patients and non-leukemic bone marrow
cells. To control for possible inter-individual variation in DNA
methylation patterns, we compared the ALL cells from each
individual patient with ‘‘normal’’ mononuclear cells isolated
from bone marrow of the patients during follow-up of the
treatment when the patients were in remission. We also included
bone marrow and blood cells from non-leukemic control
individuals in the comparison. It should be noted that the
diagnostic ALL samples contained $90% lymphoblasts, while
the samples at remission and the samples from the non-leukemic
control individuals consist of mononuclear cells from all normal
hematopoietic cell lineages, i.e. lymphoid, myeloid and erythroid
progenitor cells at varying stages of differentiation. The
methylation patterns of the bone marrow cells from the patients
at remission and the non-leukemic controls were indistinguish-
able from one another, and clearly distinct from the methylation
Table 3. Functions of genes with differential methylation between acute lymphoblastic leukemia cells and normal bone marrow
cells.
Gene
symbol
a Gene name Cellular function
b
ACCS 1-aminocyclopropane-1-carboxylate synthase homolog
(Arabidopsis)(non-functional)
biosynthetic process
ACY3 aspartoacylase (aminocyclase) 3 metabolic process
AMICA1 adhesion molecule, interacts with CXADR antigen 1 cell-to-cell signaling and interaction*, adhesion, leukocyte transmigration
CD300LF CD300 molecule-like family member f hematological system development and function
COL6A2 collagen, type VI, alpha 2 apoptosis*, adhesion, cell cycle
CPNE7 copine VII lipid metabolic process, transport
CR1 complement component (3b/4b) receptor 1 (Knops blood group) cell death*, cell-to-cell signaling and interaction*, adhesion,
hematological system development and function
DBC1 deleted in bladder cancer 1 cell death*, cell cycle
EYA4 eyes absent homolog 4 (Drosophila) cell death*
FAM83A family with sequence similarity 83, member A NA
FXYD2 FXYD domain containing ion transport regulator 2 growth and proliferation
LGALS8 lectin, galactoside-binding, soluble, 8 cell death*, cell-to-cell signaling and interaction*, adhesion
MYBPC2 myosin binding protein C, fast type adhesion
MYO3A myosin IIIA NA
PI16 peptidase inhibitor 16 NA
RUNDC3B RUN domain containing 3B NA
RYR3 ryanodine receptor 3 cell-to-cell signaling and interaction*
SEC14L4 SEC14-like 4 (S. cerevisiae) transport
THSD7A thrombospondin, type I, domain containing 7A NA
TMEM2 transmembrane protein 2 NA
UQCRFS1 ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 cell death*, cell cycle
WDR35 WD repeat domain 35 cell death*, cell cycle
ZNF462 zinc finger protein 462 NA
ZNF502 zinc finger protein 502 NA
aGene symbol according to the HUGO Gene Nomenclature Committee (http://www.genenames.org/).
bAccording to Ingenuity Pathway Analysis (IPA);
*indicates enriched cellular function P,0.05; NA indicates undefined cellular function.
doi:10.1371/journal.pone.0034513.t003
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exact proportion between the mononuclear cell types may have
varied between the individual remission or control samples. Yet,
the biological roles of the differentially methylated genes justify
that they could be further explored as diagnostic markers for
ALL.
Our hypothesis when selecting the 413 genes for methylation
analysis based on ASE analysis was that hypermethylation of CpG
sites in gene promoter regions may cause ASE by silencing the
expression of one of the alleles of expressed genes, and that
hypomethylation of one allele could allow expression of only one
of the alleles of a gene. ASE can be one-directional, so that all
individuals over-express the same allele, or bi-directional, so that
either of the two alleles may be over-expressed in different
individuals. The majority of the CpG sites in Table 2 displayed
methylation differences with absolute Db-values near 0.5, which
could reflect complete methylation or lack of methylation of a
CpG site on one of the alleles of a gene in the individual ALL cells,
as opposed to complete or no methylation of the corresponding
CpG site in the normal cells. Of the 22 genes identified in the
present study for which ASE data was available, 73% (16/22)
displayed bi-directional ASE in ALL cells [4], indicating that
stochastic methylation or de-methylation of either allele could
cause ASE. Our study confirmed the ALL-specific hypermethyla-
tion of three genes (DBC1, RUNDC3B, and COL62A) [23,24,25].
Eight of the differentially methylated CpG sites identified here
have been included subtype-specific classifiers for ALL (Table S2)
[11]. Although the methylation levels for these sites differs between
ALL subtypes, the methylation levels of 27 out of 28 of the sites in
the BCP and T-ALL samples deviated from the bone marrow
samples at remission in the same direction, indicating that most of
these CpG sites reflect ‘‘global’’ ALL-specific changes independent
of subtype. The CpG site that was differentially methylated
between ALL immuno-phenotypes is located in the MYBPC2 gene
and is previously known for distinguishing between BCP and T-
ALL [11]. Furthermore, eight of the genes (COL6A2, EYA4,
MYO3A, RUNDC3B, RYR3, SEC14L4, ZNF462, and ZNF502) were
highlighted in our previous study as potential markers for clinical
outcome in two subtypes of ALL [11]. Thus, it appears that the
aberrant methylation in these genes was acquired in the ALL cells,
which renders them potentially interesting targets for studying the
molecular events that lead to ALL. According to pathway analysis,
the genes identified here are enriched for important cellular
functions like cell-to-cell signaling and interaction or apoptosis
(P,0.05). The majority of the genes that we identified in our study
are hypermethylated in the ALL cells compared to controls, and
for 9 out of the 20 genes for which published mRNA expression
data from ALL cells was available [16,17], the methylation levels
determined in our study show evidence for an inverse relationship
with gene expression.
We conclude that our candidate gene approach based on an
initial genome-wide survey of ASE in ALL cells was a viable
approach to zoom in on genes with methylation signatures that are
characteristic of ALL cells and that have plausible functions for the
development of ALL. Whether the aberrant methylation patterns
in ALL cells were acquired stochastically or is an epigenetic mark
characteristic of the leukemia initiating cell [31] will be a key
question to address using new tools for genome-wide methylation
analysis in future studies.
Supporting Information
Figure S1 Boxplots showing validation of the Gold-
enGate Assay by Sanger sequencing. Bisulfite-converted
DNA from eight ALL samples was PCR amplified and sequenced
at five randomly chosen CpG sites in five genes (ZNF502
chr3:44,729,363, TNIK chr3:172,661,831, LOXHD1
chr18:42,435,264, NOTCH3 chr19:15,172,990, and NKAIN4
chr20:61,357,043). The methylation status of the C nucleotide in
the CpG site as detected by Sanger sequencing (horizontal axis) is
plotted against the Beta-values measured by the GoldenGate assay
(vertical axis). The data is from Milani et al. [11].
(PDF)
Table S1 Data across 1,320 CpG sites for all samples included in
the study.
(XLSX)
Table S2 Reproducibility of the DNA methylation analysis and
the methylation levels of the 28 CpG sites with differential
methylation according to ALL immuno-phenotype.
(XLSX)
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